ICCPP ODM+ Won Two Muse Design Gold Awards, Keeping Leading the Creative Design Trend
15.9.2023 15:00:00 EEST | Business Wire | Press release
Recently, the winners of MUSE Design Awards 2023, known as the Oscar Awards of the design, were announced, and ICCPP ODM+'s Cyclo eco-friendly e-cigarette and SPEEX X1, one of SPEEX dual-coils and screen display series display products, stood out and won Gold Awards of Muse Design from nearly 40,000 works worldwide, thanks to their advanced globalization vision, innovative user-centered design, and sustainable concepts of caring for both human beings and nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904756304/en/
ICCPP ODM+ Won MUSE DESIGN GOLD AWARDS (Photo: Business Wire)
MUSE Design Awards was founded in 2015 by International Awards Associates (IAA), a long-established U.S.-based international design awards association, and is one of the most influential international awards in the field of global creative design. The awards have always been known for their rigorous judging system and high quality standards, aiming to cultivate, promote and recognize excellence in the global design field, and promote the development of the global design industry to a higher level.
ICCPP ODM+ won the two design gold awards in one go in its first competition, which was not only a confirmation of its global leadership in future-oriented innovative product design, concepts and inspirations, but also a recognition of the strength of ICCPP Group's user-centered approach to deepening innovation and empowering the development of the e-atomization industry, and even set a new benchmark for global brands in e-cigarette product design.
It is understood that one of the Gold Award winners, SPEEX X1 is an independent innovative flagship product of the SPEEX heating technology series with high-capacity, dual coil and screen display from ICCPP ODM+, listed in August. It is a unique combination of dual-coil design with dual output working models and SPEEX rocket-like heating technology, and plus the small, rounded, extremely compact and aesthetic design, superimposed on the 0.73-inch oversized e-liquid and power remain screen display, SPEEX X1 achieves a perfect balance among the flavor, vapor, aesthetics and user thinking.
Cyclo, the other winner of Muse Design Gold Awards, is a new 2ml product launched by ICCPP ODM+ at VAPER EXPO UK2023 in May. Considering global trend of low carbon and environmentally friendly concept, coupled with the deep concerns of global users about increasingly serious environmental problems caused by the prevalence of disposable e-cigarettes, as well as the enforce reality of Europe's new Battery Law and some environmental protection acts, ICCPP ODM+ innovatively developed Cyclo, the world's first double environmentally-friendly concept disposable e-cigarettes solution. Through its innovative application of PLA degradable materials, coupled with lead-free and solder-free inner structures, and modularized and fully automated design, as well as the aesthetics of simple, rounded and hand-held shape, and the creative integration of the concepts of user detachable and biodegradable, Cyclo is ahead of the industry to achieve the balance of portability, artistry and recyclability for the users in advance.
While these two award-winning products are just a small microcosm of ICCPP ODM+'s human-centered, and user-first design philosophy. At ICCPP, we believe that design is not just about aesthetics, but should also keep upgrading user experience, meeting user needs and creating a more meaningful connection between people, society and nature. In the future, ICCPP ODM+ will continue to be committed to continuous innovation, to lead the design trend, to create more and more exciting and premium e-cigarette product solutions, and to bring a healthier and happier e-atomized life to vaping enthusiasts around the world.
For more information, please refer to: https://www.iccpp.com/
WARNING: This product contains nicotine which is a highly addictive substance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904756304/en/
Contact information
Media:
Carol, carol@iccpp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom